よむ、つかう、まなぶ。
参考資料15 COVID-19 vaccine safety update; Primary series in young children and booster doses in older children and adults, ACIP September 1, 2022 (22 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000208910_00052.html |
| 出典情報 | 第85回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、令和４年度第14回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会（合同開催）（10／7）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Most frequent MedDRA Preferred Terms* in reports to VAERS following 1st booster dose
mRNA COVID-19 vaccinations, ages ≥12 years† (as of August 21, 2022)
N=57,048, non-serious reports (clinical outcomes)
N=7,217, serious reports (clinical outcomes)
Rank
Adverse event (not mutually exclusive)
n (%)
Rank
Adverse event (not mutually exclusive)
n (%)
1
Headache
7,006 (12)
1
COVID-19
2,479 (34)
2
Pyrexia/Fever
6,804 (12)
2
SARS-CoV-2 Test Positive
2,017 (28)
3
Pain
6,702 (12)
3
Dyspnoea
1,223 (17)
4
Fatigue
6,542 (11)
4
Death
794 (11)
5
Chills
5,310 (9)
5
Asthenia
730 (10)
6
COVID-19
4,957 (9)
6
Pyrexia/Fever
651 (9)
7
Pain In Extremity
4,272 (7)
7
Fatigue
646 (9)
8
Nausea
3,548 (6)
8
Vaccine Breakthrough Infection
618 (9)
9
Dizziness
3,353 (6)
9
Condition Aggravated
615 (9)
10
Urticaria
3,240 (6)
10
Chest Pain
578 (8)
* Medical Dictionary for Regulatory Activities Preferred Terms (https://www.meddra.org/how-to-use/basics/hierarchy)
†
Among persons receiving Pfizer-BioNTech dose 3: children and adolescents ages 12–15 years vaccinated during January 3–August 21, 2022, and ages 16–17 years vaccinated during
December 9, 2021–August 21, 2022; adults ages ≥18 years vaccinated during September 22, 2021–August 21, 2022. Among persons receiving Moderna dose 3: adults ages ≥18 years
vaccinated during October 20, 2021–August 21, 2022.
22
mRNA COVID-19 vaccinations, ages ≥12 years† (as of August 21, 2022)
N=57,048, non-serious reports (clinical outcomes)
N=7,217, serious reports (clinical outcomes)
Rank
Adverse event (not mutually exclusive)
n (%)
Rank
Adverse event (not mutually exclusive)
n (%)
1
Headache
7,006 (12)
1
COVID-19
2,479 (34)
2
Pyrexia/Fever
6,804 (12)
2
SARS-CoV-2 Test Positive
2,017 (28)
3
Pain
6,702 (12)
3
Dyspnoea
1,223 (17)
4
Fatigue
6,542 (11)
4
Death
794 (11)
5
Chills
5,310 (9)
5
Asthenia
730 (10)
6
COVID-19
4,957 (9)
6
Pyrexia/Fever
651 (9)
7
Pain In Extremity
4,272 (7)
7
Fatigue
646 (9)
8
Nausea
3,548 (6)
8
Vaccine Breakthrough Infection
618 (9)
9
Dizziness
3,353 (6)
9
Condition Aggravated
615 (9)
10
Urticaria
3,240 (6)
10
Chest Pain
578 (8)
* Medical Dictionary for Regulatory Activities Preferred Terms (https://www.meddra.org/how-to-use/basics/hierarchy)
†
Among persons receiving Pfizer-BioNTech dose 3: children and adolescents ages 12–15 years vaccinated during January 3–August 21, 2022, and ages 16–17 years vaccinated during
December 9, 2021–August 21, 2022; adults ages ≥18 years vaccinated during September 22, 2021–August 21, 2022. Among persons receiving Moderna dose 3: adults ages ≥18 years
vaccinated during October 20, 2021–August 21, 2022.
22